NASA seeks a new Director for the NASA Astrobiology Institute (NAI). The ideal candidate will be an internationally recognized scientist with proven experience in leading or managing large interdisciplinary research programs or projects, possessed with a vision for leading the Institute into the future. Applicants for this position should have a broad scientific perspective on astrobiology, experience in conducting interdisciplinary scientific research, and demonstrated skills needed to harness the strengths of disparate research communities towards a greater goal. S/he should understand how to grow a research endeavor and respond to changing budget climates while focusing on maximizing the scientific return on NASA's investments in astrobiology. S/he should have experience in leading a diverse staff ranging from established scientists to support personnel, resource planning, and executing budgets and schedules. S/he should be comfortable with modern information technologies and distributed research teams. NASA is particularly interested in applicants who will find ways to infuse astrobiology into NASA flight missions.

The NAI Director is both the senior scientific officer and chief operating officer of the NAI. The Director coordinates scientific activities of the Institute’s member teams and is responsible and held accountable for all operational aspects of the NAI, including the administration of personnel, budget and NASA policies. The Director will lead the NAI in fulfilling its mission to perform, support, and catalyze collaborative interdisciplinary astrobiology research; train the next generation of astrobiologists; provide scientific and technical leadership for astrobiology space mission investigations; develop new information technology approaches for collaborations among widely distributed investigators; and support K-12 education and public outreach programs.

Established in 1998 as part of NASA's Astrobiology Program, the NAI is a virtual, distributed organization of competitively-selected teams that conduct and integrate astrobiology research and training programs in concert with the national and international science communities. The Institute has 12 teams including ~600 researchers distributed across ~100 organizations as well as 13 international partner organizations. Headquartered at NASA Ames Research Center in the heart of California’s Silicon Valley, the NAI links researchers across the US and around the globe using modern information technologies.

The NAI serves a vital role in advancing the goals of the larger NASA Astrobiology Program, with a focus on seeking answers to these fundamental questions: How does life begin and evolve? Is there life beyond Earth and, if so, how can we detect it? What is the future of life on Earth and beyond?

U.S. citizenship is required for the NAI Director. Interested individuals should apply directly to USAJobs at www.usajobs.gov. In the keyword search box, type vacancy number “AR15500001”. Select “Director, NASA Astrobiology Institute”, then click “Apply Online”.

NASA Ames Research Center does not discriminate in employment on the basis of race, color, religion, sex, national origin, political affiliation, sexual orientation, gender identity, marital status, disability and genetic information, age, membership in an employee organization, or other non-merit factor.
Tenure Track Positions at the Seaver Autism Center at Mount Sinai

The Seaver Autism Center is seeking researchers at the Assistant, Associate, or Full Professor levels who focus on patient-based research in autism spectrum disorder (ASD). Up to three positions are available, with at least one position prioritized for a clinician-scientist (MD or clinical psychologist) who would help manage the clinical research program. Successful applicants will have a very competitive track record in publications, and, for more senior applicants, in federal funding. Generous startup packages are available. Applicants will be members of one or more relevant Departments and Institutes at Mount Sinai.

About the Seaver Autism Center: The Seaver Autism Center integrates research at all levels. The Center includes clinical and research genetics, model systems research, controlled trials for behavioral and pharmacological interventions, biomarker development, development of assessments and screeners, large scale epidemiological studies of ASD risk factors, and neuroimaging, as well as clinical services for ASD. Psychiatrists, psychologists, neurologists, pediatricians, and clinical geneticists carry out comprehensive assessments for families and for research. The Center has a commitment to more severely affected individuals, and has taken a unique genetics-first approach to ASD research. Exceptional applicants working in any of these areas, or in additional areas of importance in ASD, are encouraged to apply.

Contact Us: Interested applicants should send a CV, a three-page summary of future research plans, and contact information for three references to:

Joseph D. Buxbaum, PhD
Director, Seaver Autism Center for Research and Treatment
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, NY
theseavercenter@mssm.edu

About Mount Sinai Health System: Internationally regarded for its dedication to medical science, Mount Sinai is home to an array of leading research institutes, centers, and laboratories, all of which work toward rapidly translating advances in basic science into innovative patient care. With a history rich in clinical milestones and an unequaled passion for patient-focused research, Mount Sinai has pioneered breakthroughs benefiting untold numbers of lives. The Mount Sinai Health System is also committed to providing compassionate patient care by recruiting the most skilled professionals for our patients. Join us if you share our vision of collaborative problem solving and help to shape the future of research and health care. In addition to taking the best care of our patients, we offer our employees a highly competitive compensation and benefits package, including medical, dental, vision, prescription drug coverage, a 403(b) retirement plan, and much more.

Formed in September 2013, Mount Sinai Health System combines the excellence of the Icahn School of Medicine at Mount Sinai with seven premier hospital campuses, including Mount Sinai Beth Israel, Mount Sinai Beth Israel Brooklyn, The Mount Sinai Hospital, Mount Sinai Queens, New York Eye and Ear Infirmary of Mount Sinai, Mount Sinai Roosevelt, and Mount Sinai St. Luke’s.

The Mount Sinai Health System is committed to the tenets of diversity and workforce that are strengthened by the inclusion of and respect for our differences. We offer our employees a highly competitive compensation and benefits package, a 403(b) retirement plan, and much more. The Mount Sinai Health System is an Equal Opportunity Employer. We promote recognition and respect for individual and cultural differences, and we work to make our employees feel valued and appreciated, whatever their race, gender, background, or sexual orientation. EOE Minorities/Women/Disabled/Veterans

---

The University of Konstanz, belongs to the universities in Germany whose “future concepts for top-class research at universities” is promoted within the framework of the Excellence Initiative of the German federal and state governments.

The Zukunftskolleg of the University of Konstanz is offering:

**up to five ZIF Marie Curie 5-year Research Fellowships**

in any discipline represented at the University of Konstanz for the development and implementation of individual research projects (Salary Scale 14 TV-L).

Fellowships will begin on March 1, 2016, and end on February 28, 2021.

**Reference number 2015/031**

Applications, supporting materials, and two letters of reference should be submitted in English by May 18, 2015, 17:00 h (Konstanz time) using the Online Application Platform:

www.zukunftskolleg.uni-konstanz.de/online-application.

Details concerning the application, required documents, and information about the Zukunftskolleg are available on our website:

http://www.zukunftskolleg.uni-konstanz.de.

**Contact:** Help Desk, Zukunftskolleg-application@uni-konstanz.de,
Anda Lohan, e-mail: a.lohan@uni-konstanz.de.

---

The University of Konstanz, belongs to the universities in Germany whose “future concepts for top-class research at universities” is promoted within the framework of the Excellence Initiative of the German federal and state governments.

The Zukunftskolleg of the University of Konstanz is offering:

**up to six ZIF Marie Curie 2-year Postdoctoral Fellowships**

in any discipline represented at the University of Konstanz for researchers in the early stage of their career, so as to enable them to develop and implement individual and independent research projects (Salary Scale 13 TV-L).

Fellowships will begin on February 1, 2016, and end on January 31, 2018.

**Reference number 2015/032**

Applications, supporting materials, and two letters of reference should be submitted in English by May 18, 2015, 17:00 h (Konstanz time) using the Online Application Platform:

www.zukunftskolleg.uni-konstanz.de/online-application.

Details concerning the application, required documents, and information about the Zukunftskolleg are available on our website:

http://www.zukunftskolleg.uni-konstanz.de.

**Contact:** Help Desk, Zukunftskolleg-application@uni-konstanz.de,
Anda Lohan, e-mail: a.lohan@uni-konstanz.de.
We invite applications for the position of

Scientific Director and Chairman (m/f) of the Management Board of the DKFZ Foundation

(Ref.no. 30/2015)

Effective as of 1 September 2015.

The DKFZ is among the world’s leading centers of cancer research and the largest biomedical research institute in Germany. From its founding in 1964, the DKFZ has pursued a threefold mission: to investigate the mechanisms leading to the development of cancer, to identify and study cancer risk factors and to develop new approaches for the diagnosis, treatment and prevention of cancer diseases. Building on its excellent basic research, the DKFZ has in recent years considerably expanded its activities in the area of translational research.

Together with the University of Heidelberg, the Heidelberg University Clinic and the German Cancer Aid, the DKFZ has established the National Center for Tumor Diseases (NCT), which has become one of the most influential institutions of translational cancer research in Europe. A new branch of the NCT will shortly be established in Dresden.

The DKFZ is the parent organization of the German Consortium for Translational Cancer Research (DKTK), a joint initiative launched by the German Federal Government and the German States with the aim of ensuring the comprehensive transfer of research results from the laboratory into clinical practice at seven partner sites throughout Germany.

The DKFZ employs around 2,750 staff members, including 1,250 scientists. The total annual budget (institutional funding, project funding and own revenues) amounts to around 250 million Euros.

The Chairman of the Management Board as the scientific representative of the foundation is jointly responsible, together with the Administrative Member of the Management Board, for overseeing the DKFZ.

The scientific departments and research groups of the DKFZ as well as the central scientific core facilities report directly to the Chairman of the Management Board. In particular, his/her responsibilities include the strategic research orientation, the oversight of the quality of the research results in conjunction with the supervisory bodies and the Board of Trustees, and the scientific development and strategic positioning of the DKFZ, both nationally and internationally. In his/her capacity as Scientific Director of the DKFZ, he/she is also spokesperson for the German Consortium for Translational Cancer Research (DKTK).

The size and scope of research carried out at the DKFZ as well as its many close collaborations with universities, research institutions and industry partners require a candidate who combines exceptional leadership qualities, international stature and outstanding scientific expertise, who is capable of providing visionary leadership to guide the strategic development of complex research structures in basic and clinical biomedical research. He/she should demonstrate an established record of management experience leading large, distinguished scientific or medical institutions. Further requirements include strategic vision, an authoritative personality, and a talent for inspiring people to work together effectively. He/she should have the stature and communicative skills to represent the DKFZ convincingly – with regard to both internal bodies and external partners. The continuous development of relations with representatives of political bodies, science, industry and relevant societal groups are of particular importance for the DKFZ. An excellent knowledge of German and English is required.

The appointment will be for a period of 5 years with the possibility of renewal. The remuneration is based on the compensation scheme for higher-level university professorships and will be the subject of individual negotiations.

The members of the Helmholtz Association actively seek to promote women in positions of leadership with managerial responsibilities in science and research. Applications from qualified women candidates are therefore particularly welcome.

Please send your application both electronically (by email) and by mail by March 31, 2015 to:

MinDir in Bärbel Brumme-Bothe
Chairwoman of the DKFZ Board of Trustees
and Chairwoman of the Search Committee
– Confidential/personal –

Federal Ministry for Education and Research (BMBF)
Kapelle-Ufer 1
D-10117 Berlin
baerbel.brumme-bothe@bmbf.bund.de
Faculty Position (außerordentliche Professor) in Biomedical Engineering

The Medical Faculty of the University of Bern invites applications for a faculty position in the field of Biomedical Microfluidics and Organs-on-Chip Systems dedicated for biomedical applications research. The position will be established at the ARTORG Center for Biomedical Engineering Research. The professorship will be heading the existing Lung Regeneration Technologies Group, a joint technological and clinical research effort of the ARTORG Center together with the departments of Pneumology and Thoracic Surgery at the University hospital Bern, Inselspital.

The successful candidate should have a PhD in biomedical engineering or similar fields and a proven track record in at least two of the following research areas: microfluidics, microtechnologies, cell biology, microfabrication and thin film technologies, material sciences and in the domain of cells-on-chip and organs-on-chip technologies, particularly lung-on-chip as well as advanced in-vitro models for personalized medicine applications.

The candidate is expected to continue and further strengthen the internationally recognized, interdisciplinary research program of the existing Lung Regeneration Technologies group. The focus of the research should be on organs-on-chip technologies that allow the investigation of the pathomechanisms of specific diseases as well as the testing of efficiency and toxicity of drug candidates or other chemical substances. Furthermore, a specific focus of the work should be the development of novel pharmaceutical testing methods specifically for lung diseases. However, future collaboration schemes beyond this topic shall be envisioned.

Additional prerequisites are a strong motivation and an undisputable commitment to undergraduate and graduate student education. The professorship will be embedded in the Graduate School for Cellular and Biomedical Sciences of the University of Bern and the specialized Master’s program in Biomedical Engineering, bridging the fields of engineering and clinical science and in the Master’s program in Biomedical Sciences.

Candidates should demonstrate a successful track record in the acquisition of competitive third party funding. Experience in professional leadership, budgeting and administration of at least a medium-sized research group is essential. In order to assure high socio-economic impact of research program, the candidate should provide expertise in technology transfer to clinics and industry and in the planning and conducting of clinical trials evaluating novel technologies.

Collaboration with other groups within the ARTORG Center of the University of Bern as well as with other academic institutions, nationally and internationally are expected. In particular he/she is expected to continue the existing intensive collaboration with the associated clinical departments.

With a view towards increasing the proportion of female professors, the University of Bern specifically encourages female candidates to apply. For more information, please contact Professor Aurel Perren, president of the electoral committee, e-mail: aurel.perren@pathology.unibe.ch. Applications with the usual documents are to be sent until 07 April 2015 electronically to the Dean’s Office (bewerbungen@meddek.unibe.ch).

Information regarding the required documents can be found under: http://www.medizin.unibe.ch/content/akademischelaufbahn/vorgehen_bewerbungen/

The University of Tennessee Health Science Center

Open-Rank, Tenure-Track Faculty Position in the Department of Genetics, Genomics and Informatics

The Department of Genetics, Genomics and Informatics at the University of Tennessee, College of Medicine seeks outstanding candidates for open-rank, tenure-track faculty positions with a research focus in translational genomics, genome informatics, or systems genetics. Investigators working at the interface between genetics, neuroscience, human development, and pharmacogenomics are particularly encouraged to apply. Applicants should demonstrate the ability to conduct high quality research, secure extramural funding, teach relevant courses, and advise students in degree programs. Rank of appointment and seed funds will match experience, productivity, and support history. Applicants should possess a doctoral degree (PhD, MD.) in genetics, genomics, bioinformatics, or a related discipline at the time of appointment.

The new Department of Genetics, Genomics and Informatics is made up of a small group of basic science faculty with research interests in the genetics of complex diseases using murine models. A larger group of faculty with expertise in human genetics (and potential collaborators) are housed in other departments and colleges at UTHSC and affiliated institutions—including the Oak Ridge National Laboratory, St Jude Children’s Research Hospital, and the University of Memphis. UTHSC is a research hub for the field of systems genetics and has been responsible for the creation of new models and novel statistical genetic approaches (see www.genenetwork.org).

Review of applications will begin on April 1, 2015 and will continue until the positions are filled. The anticipated start date is July 1, 2015. Please forward by email your complete curriculum vitae, a brief statement of research (ongoing and planned), and names and email addresses of three professional references. Address material to: genetcs@uthsc.edu, attention of Robert W. Williams, Chair, UTHSC, 855 Monroe Ave, Suite 501 Memphis TN 38163.

The University of Tennessee is an EEO/AA Title VI/Title IX/Section 504/ADA/ADAEV institution in the provision of its education and employment programs and services.
May 26 - 31, 2015
Poster Abstract Deadline: April 5

Topics:

- Chromosome Biology
- Nuclear Structure
- Chromatin & Epigenetics
- Gene Regulation & Control
- Developmental Regulation
- RNA as Controlling Elements
- Maintenance of Genome Stability
- Nuclear Receptors, Clocks & Aging
- Evolution
- Editing & Manipulation

Speakers:

Karen Adelman, National Institute of Environmental Health Sciences
Genevieve Almouzni, Institut Curie / CNRS, France
Angelika Amon, Massachusetts Institute of Technology
Shelley Berger, University of Pennsylvania
Wendy Bickmore, MRC Human Genetics Unit, UK
Gerd Blobel, Children's Hospital of Philadelphia
Jef Boeke, NYU Langone Medical Center
Julius Brennecke, Institute of Molecular Biotechnology, Austria
Anne Brunet, Stanford University
Emmanuelle Charpentier, Helmholtz Center for Infection Research, Germany
Xavier Darzacq, University of California, Berkeley
Titia de Lange, The Rockefeller University
Job Dekker, University of Massachusetts Medical School
Jennifer Doudna, University of California, Berkeley / HHMI
Denis Duboule, University Geneva & EPFL, Switzerland
Stephen Elledge, Harvard Medical School
Ronald Evans, Salk Institute for Biological Studies
Anne Ferguson-Smith, University of Cambridge, UK
Susan Gasser, Friedrich Miescher Institute, Switzerland
David Gilbert, Florida State University
Christopher Glass, University of California, San Diego
Shiv Grewal, National Cancer Institute
Gregory Hannon, Cancer Research UK Cambridge Institute

Organizers:

Terri Grodzicker, David Stewart & Bruce Stillman, Cold Spring Harbor Laboratory

Speakers (continued):

Edith Heard, Curie Institute / CNRS, France
Steve Jacobsen, University of California, Los Angeles
Rudolf Jaenisch, Whitehead Institute for Biomedical Research
Alexander Johnson, University of California, San Francisco
James Kadonaga, University of California, San Diego
Scott Keeney, Memorial Sloan-Kettering Cancer Center
David Kingsley, Stanford University
Mitch Lazar, University of Pennsylvania
Jeannie Lee, Massachusetts General Hospital
Arnold Levine, Simons Center for Systems Biology
Michael Levine, University of California, Berkeley
Susan Lindquist, Whitehead Institute for Biomedical Research
Dan Littman, NYU School of Medicine / HHMI
Susanne Mandrup, University of Southern Denmark
Tom Maniatis, Columbia University Medical Center
Robert Martienssen, Cold Spring Harbor Laboratory
Thomas Mistelli, National Cancer Institute
Richard Morimoto, Northwestern University
Huck-Hui Ng, Genome Institute of Singapore
Svante Paabo, Max-Planck Institute, Germany
David Page, Whitehead Institute for Biomedical Research / HHMI
David Pellman, Dana-Farber Cancer Institute
Nicholas Proudfoot, University of Oxford, UK
Wolf Reik, The Babraham Institute, UK
Danny Reinberg, NYU School of Medicine / HHMI
Bing Ren, University of California, San Diego
Gary Ruvkun, Massachusetts General Hospital
Mitinori Saitou, Kyoto University, Japan
Ulrich Schibler, University of Geneva, Switzerland
Robert Singer, Albert Einstein College of Medicine
Davor Solter, Max-Planck Institute of Immunobiology & Epigenetics, Germany
David Spector, Cold Spring Harbor Laboratory
Alexander Tarakhovsky, The Rockefeller University
Robert Tjian, University of California, Berkeley / HHMI
Maria-Elena Torres-Padilla, IGBMC, France
Didier Trono, EPFL, Switzerland
Bas Van Steensel, Netherlands Cancer Institute
Stephen West, London Research Institute, UK
Joanna Wysocka, Stanford University
Richard Young, Whitehead Institute for Biomedical Research
Virginia Zakian, Princeton University
Kenneth Zaret, University of Pennsylvania
Feng Zhang, Massachusetts Institute of Technology

www.cshl.edu/meetings